Literature DB >> 3022779

Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.

A P Simmonds, P S Hamilton, H Kerr, K Harvey, P Moyes, K G Davidson, A Faichney.   

Abstract

Lung tumours of non small cell pathology were cultured by clonogenic assay in several media. Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE) meant that only 23% of the original number produced significant drug results. Comparison of rat erythrocyte lysate (REL) medium with serum free defined medium (HITES) and HITES + 10% FBS demonstrated clear enhancement of PE in REL although growth was 100% successful in all these media. Ninety-three percent of samples tested against drugs in REL produced significant results. A later comparison of REL with McCoy's 5A + rbc +/- hydrocortisone produced relatively poor culture success for these 3 media and equivocal growth patterns. Low PE was attributed to age of rats used for rbc. Vindesine and cis-platinum cytotoxicity in spleen conditioned medium were 61% and 15% sensitivity respectively. These do not concur with clinical experience but the figures for overt resistance, at 39% and 69%, correspond with expected non-responders to these regimes. Drug testing in REL produced figures correlating more closely with clinical performance at 45% sensitivity to platinum and 36% of patients sensitive to both drugs, but the vindesine sensitivity at 55% is again discrepant with performance of this drug as a single agent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022779      PMCID: PMC2001492          DOI: 10.1038/bjc.1986.213

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  The effect of erythrocytes on mouse bone marrow colony development in vitro.

Authors:  T R Bradley; P A Telfer; P Fry
Journal:  Blood       Date:  1971-09       Impact factor: 22.113

2.  Studies on a human melanoma cell line: effect of cell crowding and nutrient depletion on the biophysical and kinetic characteristics of the cells.

Authors:  J W Sheridan; R J Simmons
Journal:  J Cell Physiol       Date:  1981-04       Impact factor: 6.384

3.  Biopsy of thoracic neoplasms for assay of chemosensitivity. New indication for thoracotomy.

Authors:  C A Bertelsen; D H Kern; L R Kaiser; B D Mann; E C Holmes; D L Morton
Journal:  Arch Surg       Date:  1983-09

4.  In vitro assessment of antineoplastic therapy. New indication for thoracotomy?

Authors:  L R Kaiser; D H Kern; M Campbell; B D Mann; E C Holmes
Journal:  J Thorac Cardiovasc Surg       Date:  1981-10       Impact factor: 5.209

5.  Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study.

Authors:  J A Elliott; S Ahmedzai; D Hole; A J Dorward; R D Stevenson; S B Kaye; S W Banham; B H Stack; K C Calman
Journal:  Eur J Cancer Clin Oncol       Date:  1984-08

6.  Primary bioassay of human tumor stem cells.

Authors:  A W Hamburger; S E Salmon
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

7.  Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung.

Authors:  D N Carney; P A Bunn; A F Gazdar; J A Pagan; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

8.  Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay.

Authors:  A P Simmonds; E C McDonald
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

9.  An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents.

Authors:  V D Courtenay; J Mills
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

  9 in total
  1 in total

1.  Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro.

Authors:  A P Simmonds; P Moyes; A Nicol; K G Davidson; A Faichney
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.